532384 Stock Overview
Tyche Industries Limited manufactures and sells active pharmaceutical ingredients and intermediates in India.
Tyche Industries Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹127.10|
|52 Week High||₹252.00|
|52 Week Low||₹118.00|
|1 Month Change||-15.94%|
|3 Month Change||-22.52%|
|1 Year Change||-47.57%|
|3 Year Change||98.59%|
|5 Year Change||78.64%|
|Change since IPO||2,442.00%|
Recent News & Updates
|532384||IN Pharmaceuticals||IN Market|
Return vs Industry: 532384 underperformed the Indian Pharmaceuticals industry which returned -13.1% over the past year.
Return vs Market: 532384 underperformed the Indian Market which returned 10.9% over the past year.
|532384 Average Weekly Movement||8.4%|
|Pharmaceuticals Industry Average Movement||6.8%|
|Market Average Movement||7.0%|
|10% most volatile stocks in IN Market||10.0%|
|10% least volatile stocks in IN Market||4.7%|
Stable Share Price: 532384 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: 532384's weekly volatility (8%) has been stable over the past year.
About the Company
Tyche Industries Limited manufactures and sells active pharmaceutical ingredients and intermediates in India. It also provides chiral intermediates and nutraceuticals; and contract drug substance and analytical development, as well as contract manufacture services. The company primarily exports its products to the United States and Europe.
Tyche Industries Fundamentals Summary
|532384 fundamental statistics|
Is 532384 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|532384 income statement (TTM)|
|Cost of Revenue||₹298.92m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||8.72|
|Net Profit Margin||14.14%|
How did 532384 perform over the long term?See historical performance and comparison
0.8%Current Dividend Yield
Is Tyche Industries undervalued compared to its fair value and its price relative to the market?
Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 532384 (₹127.1) is trading below our estimate of fair value (₹180.04)
Significantly Below Fair Value: 532384 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 532384 is good value based on its PE Ratio (14.6x) compared to the Indian Pharmaceuticals industry average (20.4x).
PE vs Market: 532384 is good value based on its PE Ratio (14.6x) compared to the Indian market (20x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 532384's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 532384 is good value based on its PB Ratio (1.3x) compared to the IN Pharmaceuticals industry average (2.6x).
How is Tyche Industries forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Tyche Industries has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Tyche Industries performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 532384 has high quality earnings.
Growing Profit Margin: 532384's current net profit margins (14.1%) are lower than last year (28.7%).
Past Earnings Growth Analysis
Earnings Trend: 532384's earnings have grown significantly by 30.9% per year over the past 5 years.
Accelerating Growth: 532384's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 532384 had negative earnings growth (-59.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (13.6%).
Return on Equity
High ROE: 532384's Return on Equity (8.9%) is considered low.
How is Tyche Industries's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 532384's short term assets (₹959.1M) exceed its short term liabilities (₹128.4M).
Long Term Liabilities: 532384's short term assets (₹959.1M) exceed its long term liabilities (₹28.9M).
Debt to Equity History and Analysis
Debt Level: 532384 is debt free.
Reducing Debt: 532384 has no debt compared to 5 years ago when its debt to equity ratio was 10.6%.
Debt Coverage: 532384 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 532384 has no debt, therefore coverage of interest payments is not a concern.
What is Tyche Industries's current dividend yield, its reliability and sustainability?
Dividend Score 4/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 532384's dividend (0.79%) is higher than the bottom 25% of dividend payers in the Indian market (0.36%).
High Dividend: 532384's dividend (0.79%) is low compared to the top 25% of dividend payers in the Indian market (1.61%).
Stability and Growth of Payments
Stable Dividend: 532384's dividends per share have been stable in the past 10 years.
Growing Dividend: 532384's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (11.5%), 532384's dividend payments are thoroughly covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (16.2%), 532384's dividend payments are well covered by cash flows.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Gokaraju Kumar (50 yo)
Mr. Gokaraju Ganesh Kumar has been the Managing Director of Tyche Industries Ltd., since July 31, 2008 and serves as its Chairman of the Board. He served as the Chief Financial officer at Tyche Industries...
CEO Compensation Analysis
Compensation vs Market: Gokaraju's total compensation ($USD180.45K) is above average for companies of similar size in the Indian market ($USD38.81K).
Compensation vs Earnings: Gokaraju's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Experienced Management: 532384's management team is considered experienced (3 years average tenure).
Experienced Board: 532384's board of directors are considered experienced (5.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Tyche Industries Limited's employee growth, exchange listings and data sources
- Name: Tyche Industries Limited
- Ticker: 532384
- Exchange: BSE
- Founded: 1998
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₹1.302b
- Shares outstanding: 10.25m
- Website: https://www.tycheindustries.net
Number of Employees
- Tyche Industries Limited
- H. No. C 21/A
- Road No. 9
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/12 00:00|
|End of Day Share Price||2022/05/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.